ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-FLT3/CD3 Bispecific Antibody CLN-049

Its studies are mostly in Leukemia, Myeloid, Acute, led by Cullinan Therapeutics.

Furthest: phase 2, since Oct 26, 20212 company-led studies, 2 open or runningNext primary completion: Sep 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cullinan Therapeutics22 open or runningphase 2since Oct 26, 2021Oct 26, 2021Sep 30, 2027phase 1 · NCT07722767

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 26, 2021First study: phase 2 study in Leukemia, Myeloid, AcuteFirst studyNCT05143996 · 275 planned · United States
  2. Jul 15, 2026Phase 1 study in Leukemia, Myeloid, AcuteNCT07722767 · 90 planned · United States

Ahead

  1. Sep 30, 2027Primary completion: phase 1 study in Leukemia, Myeloid, AcuteNCT07722767
  2. Dec 30, 2029Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT05143996

TargetBeta

CD3E →FLT3 →read by rule
“A T-cell-engaging, humanized, Fc-silenced immunoglobulin G1 (IgG1)-based bispecific antibody directed against both the tumor-associated antigen (TAA) FLT3 tyrosine kinase receptor (Fms-like tyrosine kinase 3; FLT3; FLT-3; CD135; fetal liver kinase-2; FLK2) and the CD3 antigen found on T-lymphocytes,”NCIt, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07722767Leukemia, Myeloid, Acute · United States1Not yet recruitingSep 30, 202790
NCT05143996Leukemia, Myeloid, Acute · United States2RecruitingDec 30, 2029275

How it is read

Names in the registry

  • “CLN-049”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.